Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular

Ganna V Kalayda1, Bart A J Jansen, Peter Wielaard

  • 1Gorlaeus Laboratories, Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA, Leiden, The Netherlands.

Insights

New platinum complexes and their anthraquinone ligands show high cytotoxicity against osteosarcoma cells and overcome cisplatin resistance. Cellular processing is similar in resistant and sensitive cells, unlike in ovarian cancer lines where lysosomal sequestration confers resistance.

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Platinum-based drugs are crucial in cancer chemotherapy but face challenges with drug resistance.
  • Anthraquinone derivatives have shown potential biological activities.
  • Understanding cellular processing is key to overcoming drug resistance mechanisms.

Purpose of the Study:

  • To evaluate the biological activity of novel N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones and their dinuclear platinum complexes.
  • To assess the efficacy of these compounds against cisplatin-sensitive and cisplatin-resistant human osteosarcoma cell lines (U2-OS and U2-OS/Pt).
  • To investigate and compare the cellular processing and distribution of these compounds in sensitive and resistant cell lines.

Main Methods:

  • Cytotoxicity assays were performed on U2-OS and U2-OS/Pt cell lines.
  • Digital fluorescence microscopy was used to study the time-dependent cellular processing of selected compounds.
  • Cellular distribution was compared between U2-OS/Pt and A2780cisR (ovarian cancer) resistant cell lines.

Main Results:

  • All evaluated compounds exhibited high cytotoxicity in U2-OS cells and effectively overcame cisplatin resistance in U2-OS/Pt cells.
  • Cellular processing of the anthraquinone ligand and its platinum complex was similar in both sensitive and resistant U2-OS cells.
  • Unlike in A2780cisR cells, sequestration in lysosomes was not observed in U2-OS/Pt cells, correlating with normal endocytosis and lack of cross-resistance.

Conclusions:

  • The novel N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinone platinum complexes are potent anticancer agents capable of overcoming cisplatin resistance.
  • Cellular processing differences, particularly lysosomal sequestration in A2780cisR cells, explain varied resistance profiles compared to U2-OS/Pt cells.
  • These findings highlight the potential of these compounds for developing new therapeutic strategies against resistant cancers.